Enhanced External Counterpulsation for Management of Postacute Sequelae of SARS-CoV-2 Associated Microvascular Angina and Fatigue: An Interventional Pilot Study

Table 1

Sociodemographic and clinical data at baseline in patients with postacute sequelae of SARS-CoV-2 (N = 10).

	n (%), unless otherwise stated
Sociodemographic data
Sex
Men	5 (50)
Women	5 (50)
Age
Mean (min-max)	50.3 (29–63)
Marital status
Single/widow/divorced	3 (30)
Married/partner, not living together	7 (70)
Cardiovascular risk factors
Smoking habit
Nonsmoker	6 (60)
Ex-smoker	4 (40)
Body mass index (kg/m^2)
≥25	9 (90)
Exact value, mean (Sd)	28.6 (3.6)
Diabetes mellitus	0
Hypertension	1 (10)
Hyperlipidemia	1 (10)
Myocardial infarction	0
Other co-morbidities
Fibromyalgia syndrome	1 (10)
Polyarthritis	1 (10)
Polymyalgia rheumatic	0
Prior anxiety/depression	4 (40)
Pulmonary disease	0
Clinical data
Systolic blood pressure (mmHg)
Mean (Sd)	127 (8.1)
Diastolic blood pressure (mmHg)
Mean, (Sd)	78 (6.8)
Heart rate (bpm)
Mean (Sd)	69 (13.7)
Ejection fraction
≥50%	10 (100)
NT-proBNP (ng/L)
Mean (Sd)	71.5 (50.81)
Pharmacologic treatments
Angiotensin-converting-enzyme-inhibitors	1 (10)
Angiotensin receptor blockers	1 (10)
Anticoagulants	0
Antidepressant	3 (30)
Antiplatelet agents	1 (10)
Asthma inhalers
Short-acting	6 (40)
Long-acting	0
Both	0
Beta blockers	5 (50)
Calcium channel blockers	6 (60)
If-inhibitor	1 (10)
Lipid-lowering agents	3 (30)
Long-acting nitrates	3 (30)

NT-proBNP, N-terminal of the prohormone brain natriuretic peptide.